RHG Real Hotel Grp

RNS Number:5505V
James Reed & Partners PLC
13 December 2005

This announcement is not for release, publication or distribution in or into or
from the United States, Canada, Australia, Japan or any other jurisdiction if to
do so would constitute a violation of the relevant laws of such jurisdiction.

For immediate release 13 December 2005

                     Reed Health Group plc ("Reed Health")

           Recommended Increased Offers declared wholly unconditional

The board of James Reed & Partners plc ('James Reed & Partners' or 'JRP')
announces that by 3.00 p.m. (UK time) on 12 December 2005, the first closing
date of the Recommended Increased Offers, valid acceptances of the Recommended
Increased Offers had been received in respect of a total of 14,915,688 Reed
Health Ordinary Shares and 26,830,580 Reed Health 'B' Shares representing
approximately 45.47 per cent. of the Reed Health Ordinary Shares and
approximately 99.96 per cent. of the Reed Health 'B' Shares respectively and, in
aggregate, approximately 69.99 per cent. of the issued share capital, and voting
rights, of Reed Health.

The above total includes acceptances in respect of 8,367,542 Reed Health
Ordinary Shares and 26,827,500 Reed Health 'B' Shares, representing, in
aggregate, approximately 59.01 per cent of the issued share capital, and voting
rights, of Reed Health, pursuant to irrevocable undertakings to accept the
Recommended Increased Offers from the Independent Directors of Reed Health and
certain other Reed Health Shareholders.

In addition, JRP owns 15,780,125 Reed Health Ordinary Shares representing
approximately 48.11 per cent. of the issued Reed Health Ordinary Shares and
approximately 26.46 per cent. of the issued share capital, and voting rights, of
Reed Health.

Therefore, JRP either owns, or has received valid acceptances of the Recommended
Increased Offers over, a total of 57,526,393 Reed Health Shares, representing,
in aggregate, approximately 96.45 per cent. of the issued share capital, and
voting rights, of Reed Health.

Save as disclosed in this announcement, neither JRP, nor any persons acting, or
deemed to be acting, in concert with JRP, held any Reed Health Shares (or rights
over Reed Health Shares) or has acquired or agreed to acquire any Reed Health
Shares (or rights over Reed Health Shares) during the Offer Period.

In accordance with the terms and conditions of the Recommended Increased Offers,
the board of JRP announces that all outstanding conditions of the Recommended
Increased Offers have either been satisfied or waived and that the Recommended
Increased Offers are therefore declared unconditional in all respects. The
Recommended Increased Offers will remain open for acceptance until further
notice.

JRP intends to procure that Reed Health applies to the London Stock Exchange and
the FSA for the cancellations, respectively, of the trading of Reed Health
Ordinary Shares on the London Stock Exchange and the listing of the Reed Health
Ordinary Shares on the Official List. It is anticipated that such cancellations
will, subject to the Listing Rules and the Rules of the FSA, take effect no
earlier then 13 January 2006, being 20 business days after the date of this
announcement that the Recommended Increased Offers are declared unconditional in
all respects.

To the extent they have not already done so, Reed Health Shareholders who hold
their Reed Health Shares in certificated form and who wish to accept the
Recommended Increased Offers should complete, sign and return their Further
Forms of Acceptance as soon as possible in accordance with the instructions set
out in the Original Offer Document, the Recommended Increased Offer Document and
in the Further Forms of Acceptance.

Reed Health Ordinary Shareholders who hold their Reed Health Ordinary Shares in
uncertificated form and who wish to accept the Recommended Increased Ordinary
Offer should send a TTE Instruction to CRESTCo in relation to such shares as
soon as possible. The procedure for acceptance of the Recommended Increased
Ordinary Offer is set out in paragraph 18 of Part II of the Recommended
Increased Offer Document.

In accordance with paragraph 14 of Part II of the Recommended Increased Offer
Document, JRP will today post proposals to the holders of options under the Reed
Health Share Option Schemes in relation to the Recommended Increased Offers.

As valid acceptances have been received in respect of more than nine-tenths in
value of the Reed Health 'B' Shares to which the Recommended Increased 'B'
Ordinary Offer relates, JRP intends to apply the provisions of sections 428 to
430F of the Companies Act to acquire compulsorily any outstanding Reed Health
'B' Shares not acquired or agreed to be acquired by or on behalf of JRP pursuant
to the Recommended Increased 'B' Ordinary Offer or otherwise. Accordingly JRP
will shortly be posting formal notices pursuant to section 429(4) of the
Companies Act 1985 to those Reed Health 'B' Shareholders who have not validly
accepted the Recommended Increased 'B' Ordinary Offer. Once valid acceptances
have been received in respect of more than nine-tenths in value of the Reed
Health Ordinary Shares to which the Recommended Increased Ordinary Offer
relates, JRP also intends then to apply the provisions of sections 428 to 430F
of the Companies Act to acquire compulsorily any outstanding Reed Health
Ordinary Shares not acquired or agreed to be acquired by or on behalf of JRP
pursuant to the Recommended Increased Ordinary Offer or otherwise.

Words and expressions defined in the Original Offer Document dated 10 November
2005 and the Recommended Increased Offer Document dated 24 November 2005 shall
have the same meaning when used in this announcement. Copies of the documents,
posted to Reed Health Shareholders on 10 November 2005 and 24 November 2005
respectively, are available for inspection at Mayer, Brown, Rowe & Maw LLP, 11
Pilgrim Street, London, EC4U 6RW.

Enquiries:

James Reed & Partners plc
James Reed / Derek Beal                                Tel: 020 8274 4467

Altium Capital Limited
Garry Levin / Tim Richardson / Marc Milmo              Tel: 020 7484 4040

Smithfield Consultants
Reg Hoare / Katie Hunt                                 Tel: 020 7360 4900

Altium Capital Limited, which is authorised and regulated in the United Kingdom
by the Financial Services Authority, is acting exclusively for James Reed &
Partners as financial adviser within the meaning of the Rules of the Financial
Services Authority and for no one else in connection with the Recommended
Increased Offers. Altium Capital Limited is not advising any other person or
treating any other person as its client in relation thereto and will not be
responsible to anyone other than James Reed & Partners for providing the
protections afforded to clients of Altium Capital Limited, or for giving advice
to any other person in relation to the Recommended Increased Offers, the
contents of this announcement or any other matter referred to herein.






                      This information is provided by RNS
            The company news service from the London Stock Exchange

EN
OUPTTBLTMMBBBPA

Reed Health (LSE:RHG)
Gráfica de Acción Histórica
De May 2024 a Jun 2024

Reed Health (LSE:RHG)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024